1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Hefei Lifeon Pharmaceutical Co., Ltd.

Hefei Lifeon Pharmaceutical Co., Ltd.

003020.SZ
Hefei Lifeon Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
15.49
CNY
-0.35
- -
2.95BMarket Cap
Hefei Lifeon Pharmaceutical Co., Ltd.
003020.SZ
(Shenzhen Stock Exchange)

Recent

price

15.49

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.6
5.45
6.02
6.39
7.24
8.75
9.74
11.18
10.08
11.39
8.25
6.62
6.82
5.39
Revenue per Share
0.23
0.29
0.34
0.42
0.48
0.56
0.62
0.8
0.76
0.92
0.98
0.7
0.72
0.59
Basic EPS, GAAP
-0.24
-0.06
0.36
0.29
- -
0.22
0.62
0.69
-0.13
-0.2
0.03
0.19
0.41
-0.39
Free Cash Flow per Basic Share
0.06
0.09
0.11
0.14
0.1
0.14
0.13
0.17
0.21
0.29
0.27
0.35
0.73
0.54
Dividend per Share
0.8
1
1.24
1.71
2.07
2.46
2.86
3.56
3.23
3.92
4.65
4.93
5.27
5.55
Book Value per Share
0.85
0.95
1.2
1.72
2.11
2.97
3.3
6.74
5.38
6.16
7.3
7.54
7.8
8.14
Tangible Book Value per Share
159
161
160
161
161
163
169
169
225
227
231
229
228
223
Basic Weighted Avg Shares
733
878
962
1,028
1,167
1,425
1,650
1,894
2,273
2,579
1,901
1,518
1,554
1,202
Sales/Revenue/Turnover
6.45
6.43
6.55
7.59
8.01
7.53
7.22
8.21
8.03
8.17
12.39
11.88
10.7
10.71
Operating Margin (%)
10
11
11
13
13
14
15
16
37
36
45
84
90
- -
Depreciation Expense
37
47
54
67
77
92
105
135
172
209
227
161
165
132
Net Income, GAAP
17.78
17.81
18.77
16.89
16.02
15.46
13.55
13.91
11.6
12.75
9.14
11.25
10.04
10.49
Effective Tax Rate (%)
5
5.36
5.59
6.56
6.59
6.43
6.37
7.13
7.58
8.11
11.93
10.58
10.63
10.94
Profit Margin (%)
40
40
60
138
208
354
413
948
892
830
608
604
656
694
Working Capital
- -
- -
- -
- -
- -
- -
- -
19
25
3
34
64
61
71
LT Debt
142
177
216
298
362
506
590
1,174
1,304
1,480
1,873
1,913
1,952
1,987
Total Equity
- -
18.88
17.64
19.78
19.97
18.6
17.74
14.78
12.65
12.82
12.37
8.11
7.39
5.57
Return on Invested Capital (%)
- -
22.14
21.44
23.48
21.93
22.51
22.49
23.92
25.19
25.37
20.05
12.74
12.14
9.6
Return on Capital (%)
- -
32.45
29.93
28.46
25.2
24.97
23.77
24.83
25.84
25.87
23.12
14.57
14.16
10.93
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
3
3
LT Borrowings
- -
60
70
LT Finance Leases
- -
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
228
228
228
Market Capitalization
5,423
4,950
4,509

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,176
1,237
Cash, Cash Equivalents & STI
- -
454
486
Accounts Receivable, Net
- -
452
435
Inventories
- -
204
228
Total Current Liabilities
- -
521
542
Payables & Accruals
- -
- -
- -
ST Debt
- -
3
3
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.04%
11.06%
2.04%
Free Cash Flow
-2,622.54%
109.03%
119.37%
Net Income, GAAP
13.28%
6.2%
2.86%
Sales/Revenue/Turnover
6.24%
-2.12%
2.33%
Total Cash Common Dividend
29.99%
47.37%
105.31%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
334
436
356
393
1,518
2025
360
372
- -
473
1,554
2026
357
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
- -
- -
- -
0.7
2025
0.17
- -
- -
- -
0.72
2026
0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.35
2025
0.17
- -
- -
- -
0.73
2026
- -
- -
- -
- -
- -
Similar Companies
Exelixis, Inc. (0IJO.L)
IMV Inc. (IMV.TO)
AnGes, Inc. (4563.T)
Brickell Biotech, Inc. (BBI)
Trevi Therapeutics, Inc. (TRVI)
Kairos Pharma, Ltd. (KAPA)
Business
Hefei Lifeon Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical preparations and active pharmaceutical ingredients (APIs). Founded in 2002 and headquartered in Hefei, Anhui Province, China, the company operates through segments including pharmaceutical industry, wholesale and distribution, and retail business, with facilities covering APIs, traditional Chinese medicine extracts, chemical preparations, and the largest osmotic pump preparation base in China. Its core products encompass APIs such as nifedipine, felodipine, doxazosin mesylate, paliperidone, prilocaine, methylphenidate hydrochloride, dimercaptosuccinic acid, paeonol, urea, and troxerutin; pharmaceutical preparations including osmotic pump products like nifedipine controlled-release tablets, felodipine extended-release tablets, doxazosin mesylate extended-release tablets, trimetazidine hydrochloride sustained-release tablets, oxycodone hydrochloride sustained-release tablets (10mg, 40mg), methylphenidate hydrochloride sustained-release tablets, and venlafaxine hydrochloride sustained-release tablets; central nervous system, cardiovascular, digestive system, ophthalmic, and external dermal medicines such as gelling ketone capsules, yiqi and gastric capsules, pitaxacin oral solution, levofloxacin eye drops, gatifloxacin eye drops, ofloxacin eye drops, benzalkonium eye drops, timolol maleate eye drops, pramoxine hydrochloride eye drops, dampitol ointment, clobetasol propionate gel, compound turmeric dermal gel, urea vitamin E cream, kunning granules, metformin glipizide tablets, and itraconazole oral liquid; as well as medical intermediates, plant extracts, and decoction pieces. The company primarily serves domestic markets in China across therapeutic areas like cardiovascular, digestive, central nervous, ophthalmology, and dermatology, with select international recognition including a 2018 FDA inspection passed with zero defects on one API facility. Recent developments include signing a nurturing agreement in March 2025 with related party Hefei Lifang Investment Group to advance innovative drug projects in mental health via Nanjing Minovic Pharmaceutical Co., Ltd., granting priority commercialization rights; and acquiring a 51% stake in Anhui Joyfar Pharmaceutical Co., Ltd. for CNY 220 million in August 2023 to expand its portfolio. Hefei Lifeon listed on the Shenzhen Stock Exchange main board (003020.SZ) in December 2020 and maintains a postdoctoral workstation while holding over 30 invention patents and honors such as National Torch Program Key High-tech Enterprise.